Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

In a move to increase access to HIV-prevention treatment, the U.S. Food and Drug Administration on Monday approved the use of Apretude – the first injectable pre-exposure prophylaxis treatment aimed ...

A little specificity would go a long way in the recommendations of the US Preventive Services Task Force (USPSTF)—that is, if we want health insurance companies to pay for lifesaving HIV prevention ...

smartphone When pre-exposure prophylaxis (PrEP), is taken daily as prescribed, sexual transmission of HIV is reduced by approximately 99% and transmission through injection drug use is reduced by at ...

The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP). The US Preventive Services Task Force (USPSTF) granted an “A” grade for HIV ...

With Gilead Sciences' stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. But, with a unique pre-exposure ...

Applying novel and effective approaches based on behavioral economics for pre-exposure prophylaxis (PrEP) dissemination programs could help to tailor the programs to the populations and settings of ...

For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. The result came from the PURPOSE 1 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous lenacapavir ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The Supreme Court heard oral arguments last month in a case that ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...